HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats.

AbstractPURPOSE:
To study the pharmacokinetics of deguelin, a naturally occurring potential cancer chemopreventive agent, in rats.
METHODS:
[3H]Deguelin was administered intravenously (i.v.) under anesthesia, and blood samples were collected over 24 h. [3H]Deguelin and metabolites were extracted from plasma with ethyl acetate, and quantified by HPLC. Data were analyzed with the WinNolin pharmacokinetic software package to determine pharmacokinetic parameters. A three-compartment first-order elimination model was used to fit the plasma concentration-time curve. In addition, deguelin concentrations in tissues after i.v. and intragastric (i.g.) administration were determined by HPLC, and excretion (feces and urine) was evaluated over a 5-day period after i.g. administration.
RESULTS:
Deguelin exhibited a mean residence time (MRT) of 6.98 h and terminal half-life (t1/2(gamma)) of 9.26 h. The area under the curve (AUC) and total clearance (Cl) were 57.3 ng.h/ml and 4.37 l/h per kg, respectively, with an apparent volume of distribution (V) and volume of distribution at steady-state (Vss) of 3.421 l/kg and 30.46 l/kg, respectively. Following i.v. administration, the relative levels of tissue distribution were as follows: heart > fat > mammary gland > colon > liver > kidney > brain > lung. Following i.g. administration, the relative levels of tissue distribution were as follows: perirenal fat > heart > mammary gland > colon > kidney > liver > lung > brain > skin. Within 5 days of i.g. administration, about 58.1% of the [3H]deguelin was eliminated via the feces and 14.4% via the urine. Approximately 1.7% of unchanged deguelin was found in the feces, and 0.4% in the urine.
CONCLUSIONS:
An initial pharmacokinetic investigation of deguelin showed that this rotenoid has a relatively long MRT and half-life in plasma in the rat. The compound distributed in the tissues and excreted as metabolites, mainly via the feces.
AuthorsG O Udeani, G M Zhao, Y G Shin, J W Kosmeder 2nd, C W Beecher, A D Kinghorn, R M Moriarty, R C Moon, J M Pezzuto
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 47 Issue 3 Pg. 263-8 (Mar 2001) ISSN: 0344-5704 [Print] Germany
PMID11320671 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticarcinogenic Agents
  • Rotenone
  • deguelin
Topics
  • Animals
  • Anticarcinogenic Agents (blood, pharmacokinetics)
  • Area Under Curve
  • Chromatography, High Pressure Liquid
  • Female
  • Half-Life
  • Rats
  • Rats, Sprague-Dawley
  • Rotenone (analogs & derivatives, blood, pharmacokinetics)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: